載入...
Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin(®)) in patients with advanced non-squamous non-small cell lung cancer
PURPOSE: The objectives of this analysis were to characterize the population pharmacokinetics (PK) of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin(®)) sourced from the European Union (bevacizumab-EU) in patients with advanced non-squamous non-small cell lung cancer (NSCL...
Na minha lista:
| 發表在: | Cancer Chemother Pharmacol |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer Berlin Heidelberg
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7036079/ https://ncbi.nlm.nih.gov/pubmed/31768697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-019-03946-8 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|